Drug Type Antibody drug conjugate (ADC) |
Synonyms M-1231, M1231 |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), MUC1 modulators(Mucin-1 modulators) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H44N4O4 |
InChIKeyILRXQTICSGMLFH-ZYRIPLEJSA-N |
CAS Registry1977557-86-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Squamous Cell Carcinoma | Phase 1 | US | 25 Jan 2021 | |
Esophageal Carcinoma | Phase 1 | US | 13 Jan 2021 | |
Esophageal Carcinoma | Phase 1 | US | 13 Jan 2021 | |
Esophageal Carcinoma | Phase 1 | CA | 13 Jan 2021 | |
Esophageal Carcinoma | Phase 1 | CA | 13 Jan 2021 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 13 Jan 2021 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 13 Jan 2021 | |
Non-Small Cell Lung Cancer | Phase 1 | CA | 13 Jan 2021 | |
Non-Small Cell Lung Cancer | Phase 1 | CA | 13 Jan 2021 |